502 results about "Severe anaemia" patented technology

Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.

The invention relates to an isoquinolone compound and application thereof. The invention in particular relates to an isoquinolone compound used as a HIF prolyl hydroxylase inhibitor (HIF-PHI) and a pharmaceutical composition thereof. Moreover, the present invention provides the application of the isoquinolinone compound or the pharmaceutical composition thereof in the preparation of a medicament for preventing or treating HIF-associated or HIF-mediated diseases as anemia or ischemia, local ischemia or hypoxia.

The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease and AI: anaemia of inflammation).

A compound of ferrous L-threonate with structure (I), its compostions and methods useful for iron supplementation for mammals, particularly for human body to improve and treat nutritional iron-deficiency anemia, blood loss anemia and hemolytic anemia.

Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.

The present invention relates to administration of milk fat or a milk fat analogue, optionally with at least one additional therapeutic factor, preferably lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof, to inhibit tumour formation or growth, maintain or improve one or more of the white blood cell count, the red blood cell count, or the myeloid cell count, reduce cachexia, mucositis, and anemia, stimulate the immune system and treat or prevent cancer and the symptoms of cancer and side-effects of cancer therapies. The methods and medicinal uses of the invention may be carried out by employing dietary (as foods or food supplements), nutraceutical or pharmaceutical compositions. Compositions useful in the methods of the invention are also provided.

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

A composite medicine for treating the hemorrhagic anemia, iron-deficiency anemia and nutritional anemia is prepared from the arnono acid chelated iron, one or more Chinese-medicinal materials for nourishing blood, and pharmacologically, acceptable salt. Its advantages are high curative rate and biologic utilization rate, and low irritation to enterogastric tract.

In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).

The invention relates to a derivative of an aza-aryl compound as shown in the formula I, and the derivative is capable of adjusting erythropoietin (EPO). The derivative comprises the sodium salt, meglumine salt, hydrobromic acid and hydrochloride of the aza-aryl compound as shown in the formula I, and is high in solubility and water stability in an aqueous medium. In addition, the inventor discovers that the derivative is effective for treating cancers and related anemia.

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

A calcium levo-pteroyglutamite injection in the form liquid or freeze dried powder for treating anemia and tumor is prepared from calcium levo-pteroyglutamite, mannitol, dextro-glycoside, glucose, sodium chloride, hydrolytic protein, at least one additive, and water for injection. Its advantages are high curative effect and low cost.

The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1):

wherein,

• • R¹, R² and R³ each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;
  • W¹ and W² each independently represent N or CH;
  • X represents O, NR⁴, CONR⁴ or NR⁴CO;
  • R⁴ each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

The invention discloses a medicine for treating AIDS, and relates to a traditional Chinese medicine. The medicine is characterized by being made from the following raw materials: 15-25g of angelica, 25-35g of astragalus root, 25-35g of morinda root, 15-25g of red sage root and 1-15g of cassia. The following bulk drugs can also be added: spatholobus stem, pepper, largehead atractylodes, achyranthes root, black bean, pilose asiabell root, sheep manure, clematis root, dried ginger, fibrous root of fistular onion, fly larval and the like. The medicine is prepared by the following steps: taking the raw materials, soaking for 30-40m, adding 700-1000g of water, decocting with slow fire for 15-25m after boiling, and separating dregs from the decoction for oral administration; and baking and grinding the dregs into powder for oral administration. The medicine has the efficacies of invigorating spleen and stomach, invigorating vital energy and producing saliva, recuperating internal organs, nourishing blood and liver, promoting blood circulation to clear channels, enriching the blood and strengthening the bone, and killing viruses. The medicine is used for treating AIDS and has the curative ratio up to 97.7%, and can be also widely applied to treating diseases such as leukemia, aplastic anemia, thrombocytopenia, hepatitis, dermatosis and the like.